Seagen to Highlight New Research from its Diverse Pipeline of Targeted Cancer Therapy Candidates at the Society for Immunotherapy of Cancer's (SITC) Annual Meeting

(marketscreener.com) – Encouraging data from ongoing Phase 1 study of SGN-B6A illustrate commitment to pioneering novel first-in-class antibody-drug conjugates –https://www.marketscreener.com/quote/stock/SEAGEN-INC-10808/news/Seagen-to-Highlight-New-Research-from-its-Diverse-Pipeline-of-Targeted-Cancer-Therapy-Candidates-at-42271646/?utm_medium=RSS&utm_content=20221110